SEC Form 4Coverage since Jun 15, 2026
$ARQT insider trading
Over the last 12 months, Arcutis Biotherapeutics insiders reported no purchases and 6 sales totaling $535K across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $535K 6 events
- Events · 12m
- 6 Form 4 filings, grouped
- Insiders · 12m
- 5 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $ARQT · 12Mvia TradingView
Top insiders · 12m
Welgus Howard G.—2× · $244K
Burnett PatrickSee Remarks1× · $25K
Matsuda MasaruSee Remarks1× · $32K
Watanabe ToddSee Remarks1× · $114K
LIN SUE-JEAN—1× · $121K
All insider trades
6 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | Burnett PatrickSee Remarks · O | ▼ Sale | 955 | $26.12 | $25K | -0.8% | plan |
| Aug 3, 2026 | Matsuda MasaruSee Remarks · O | ▼ Sale | 1,230 | $26.12 | $32K | -1% | plan |
| Aug 3, 2026 | Watanabe ToddSee Remarks · O·D | ▼ Sale | 4,375 | $26.12 | $114K | -0.6% | plan |
| Jul 15, 2026 | Welgus Howard G.D | ▼ Sale | 4,730 | $26.91 | $127K | -11.3% | plan |
| Jun 17, 2026 | Welgus Howard G.D | ▼ Sale | 4,731 | $24.58 | $116K | -11.1% | plan · 2 tranches |
| Jun 15, 2026 | LIN SUE-JEAND | ▼ Sale | 4,946 | $24.38 | $121K | -15.2% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ARQT feed.